

COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

RECENT NEWS

Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

Sep 16 2026, 8:30 AM EDT

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Sep 9 2026, 8:30 AM EDT

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Aug 27 2026, 8:30 AM EDT

STOCK OVERVIEW

Symbol	PPCB
Exchange	Nasdaq
Market Cap	2.21m
Last Price	\$0.6297
52-Week Range	\$0.595 - \$53.395

09/21/2026 08:00 PM EDT

INVESTOR RELATIONS

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

MANAGEMENT TEAM

James Nathanielsz
CEO and Executive Chairman

Dr. Ralf Brandt
Research & Development Director

Jeannine Zimmerman
Chief Financial Officer

PROPANC BIOPHARMA, INC.

302/6 Butler Street
Camberwell, VIC 3124
AU

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.